Growing influence of Chinese medicines abroad

Chinese innovative medicines experienced significant expansion in overseas markets during 2026, with the value of external licensing deals exceeding $120 billion, marking a 36% increase compared to the previous year. The average deal value continued to rise. Over 2,900 new clinical trials for drugs were registered, an 18% increase, while cell and gene therapy trials grew by 30%. Regulatory reforms led to the approval of 59 innovative drugs and 51 medical devices for market release, including 13 first-class drugs, reflecting growing confidence in Chinese innovation and attracting international investments. For example, Eli Lilly announced a $3 billion investment to expand its operations in China.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل